Empath Ventures

Empath Ventures is a venture capital firm founded in 2021 in Los Angeles, California, focused on psychedelic medicine and exponential health technologies. The firm's investment philosophy is grounded in scientific rigor applied to modern medicine, combining emerging pharmaceutical research with exponential technologies and transdisciplinary collaboration. Its thesis is built around three goals: healing the sick, preventing illness, and enhancing human health through novel therapeutic approaches. The firm has made 4 investments at Seed and Series A stages, with check sizes in the $100,000 to $2 million range. Notable portfolio companies include Psylo, a psychedelic medicine company, and Motif Neurotech, a neuro-technology firm. The team consists of six people including three partners. The firm has since rebranded to Focalpoint Partners and is also listed under the name XEIA Venture Partners on some platforms. Empath Ventures represents an emerging category of specialized healthcare venture capital focused on the psychedelics-as-medicine sector, a field that has attracted growing scientific and regulatory interest. The firm positioned itself at the convergence of biotechnology, pharmaceutical research, and health technology, backing founders working at the earliest and most scientifically uncertain stages of therapeutic development where access to patient, knowledgeable capital is most scarce.